Artivion Narrows 2026 Revenue Outlook Ahead of NEXUS Launch
Photo: TokenPost
Artivion, a cardiac and vascular surgery company, narrowed its 2026 revenue outlook after third-quarter revenue rose 9%, as it prepares for a planned January 2027 U.S. launch of its NEXUS aortic-arch stent-graft system. The company’s 2026 revenue range is now $484 million to $492 million, compared with its previous range of $480 million to $496 million. The lower end rose and the upper end fell, leaving the midpoint unchanged. The revised range represents expected growth of 8% to 10% over 2025 adjusted revenue on an adjusted constant-currency basis. The previous outlook called for growth of 7% to 11%.
Source: TokenPost
